莫德纳 MRNA

Mr. Bancel has served as our CEO since October 2011. Before joining Moderna, Mr. Bancel served for five years as CEO of the French diagnostics company bioMerieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium, and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Eli Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMerieux. He is currently a Venture Partner at Flagship Pioneering. Mr. Bancel was nominated Chevalier of the Legion d'honneur in 2022, the highest recognition in France, and was elected to the U.S. National Academy of Engineering in 2024. Other Public Boards: Qiagen N.V. (2013-2021). Education: Master of Engineering degree from Ecole Centrale Paris, Master of Science in Chemical Engineering from the University of Minnesota, M.B.A. from Harvard Business School.

Dr. Hoge oversees Moderna's commercial organization and is responsible for strategy across research & development, medical affairs and commercial functions. Before joining Moderna in January 2013, he was employed by McKinsey & Company from 2005 to 2012, in roles of increasing responsibility, most recently as a Partner and a leader in the firm's healthcare practice. Dr. Hoge was a resident physician from 2004 to 2005 at New York University/Bellevue Hospital. Education: Amherst College, B.A. in Neuroscience, University of California, San Francisco, M.D.

Mr. Mock oversees Moderna's accounting, financial planning and analysis, business development, treasury, real estate, investor relations, internal audit and tax functions. Before joining Moderna in September 2022, he was employed by PerkinElmer from 2018 to 2022 as Senior Vice President and Chief Financial Officer. Mr. Mock joined PerkinElmer from General Electric, where he served in a number of positions between 1999 and 2018, most recently as Vice President, Corporate Audit Staff. Education: St. Lawrence University, B.A. in economics.

Ms. Klinger oversees legal matters for Moderna, including corporate governance, intellectual property, litigation, compliance, privacy, as well as ESG strategy and global security. She is also the President of the Moderna Charitable Foundation. Before joining Moderna in June 2021, she was employed by Novartis from 2008 to 2021, most recently as Chief Legal Officer and a member of the Novartis Executive Committee. While at Novartis, Ms. Klinger also served as the Chief Ethics, Risk and Compliance Officer and Global Head of Litigation, and as Global Head of Legal at Sandoz, a Novartis division. She began her in-house career at Barr Laboratories before joining Solvay Pharmaceuticals as Senior Vice President and General Counsel. Ms. Klinger was previously a partner with Alston & Bird. Education: University of Notre Dame, B.A. in psychology, University of North Carolina at Chapel Hill, J.D.

Dr. Noubar B. Afeyan, PhD, Dr. Afeyan is the founder and CEO of Flagship Pioneering, a company that creates bioplatform companies to transform human health and sustainability. An entrepreneur and biochemical engineer, Dr. Afeyan holds more than 100 patents and has co-founded more than 70 life science and technology startups during his career. Dr. Afeyan entered biotechnology during its emergence as an academic field and industry, completing his doctoral work in biochemical engineering at MIT in 1987. He was a senior lecturer at MIT's Sloan School of Management from 2000 to 2016, a lecturer at Harvard Business School until 2020, and he currently serves as a member of the MIT Corporation. In 2022, Dr. Afeyan was elected to the U.S. National Academy of Engineering. Other Public Boards: Omega Therapeutics, Inc. (2016-2023), Chair, Rubius Therapeutics, Inc. (2013-2022), Seres Therapeutics, Inc. (2012-2020). Education: B.S. in Chemical Engineering from McGill University, Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology.

Dr. Nader served as President, CEO and Executive Director of NPS Pharmaceuticals from 2008 until 2015, when the company was acquired. During his tenure as CEO, Dr. Nader transformed NPS Pharma into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases. From September 2023 to January 2024, Dr. Nader served as the acting Chief Executive Officer of BenevolentAI while the company conducted a CEO search. Prior to NPS, Dr. Nader was a venture partner at Care Capital. He previously served on Aventis Pharma's North America Leadership Team, holding a number of executive positions in integrated healthcare markets and medical and regulatory affairs. Dr. Nader previously led global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc. He is a senior advisor for Blackstone Life Sciences. Dr. Nader is the former Chairman of BioNJ, New Jersey's biotechnology trade organization, and previously served on the board of the Biotechnology Industry Organization. Other Public Boards: BenevolentAI (2021-2024), Chair, Talaris Therapeutics, Inc. (2018-2023), Chair, Acceleron Pharma Inc. (2014-2021), Chair, Alexion Pharmaceuticals, Inc. (2017-2021), Prevail Therapeutics Inc. (2018-2021), Chair. Education: French doctorate in Medicine from St. Joseph University in Lebanon, Physician Executive M.B.A. from the University of Tennessee.

From 2010 to 2021, Dr. Nabel served as the President of Harvard University affiliated Brigham Health, which includes Brigham and Women's Hospital, Brigham and Women's Faulkner Hospital, and the Brigham and Women's Physician Organization. Dr. Nabel was also a Professor of Medicine at Harvard Medical School from 2010 to 2021. Following her retirement from Brigham Health, Dr. Nabel served as Executive Vice President for Strategy at ModeX Therapeutics, from 2021 to 2022, when the company was acquired by OPKO Health, Inc. Following the acquisition, Dr. Nabel also served as Chief Medical Officer for OPKO Health until August 2023. She now serves as a consultant to OPKO Health and ModeX Therapeutics. Earlier in her career, Dr. Nabel held a variety of roles, including Director, at the National Heart, Lung and Blood Institute at the National Institutes of Health, a federal agency funding research, training and education programs to promote the prevention and treatment of heart, lung and blood diseases, from 1999 to 2009. She is an elected member of the U.S. National Academy of Medicine of the U.S. National Academy of Sciences. Other Public Boards: Medtronic plc (since 2014), Lyell Immunopharma, Inc. (since 2021), Accolade, Inc. (since 2021). Education: B.A. from St. Olaf College, M.D. from Cornell University Medical College, Postgraduate training in internal medicine and cardiovascular diseases at Brigham and Women's Hospital and Harvard University.

On September 30, 2026, Moderna, Inc. announced the appointment of Juan Andres as its Chief Operating Officer effective October 5, 2026. Mr. Andres, 62, previously spent nearly six years at Moderna, including serving as its Chief Technical Operations and Quality Officer from 2018 through 2022 and as its President, Strategic Partnerships and Enterprise Expansion before retiring from Moderna in 2023. During his tenure, he led the build-out and unprecedented scale-up of Moderna's manufacturing capabilities, including the rapid expansion of the Company's global manufacturing network to support the production and supply of Moderna's COVID-19 vaccine.

Moderna Inc., announced the appointment of Michael McDonnell to its Board of Directors, effective July 8, 2026. Mr. McDonnell is a financial executive with substantial experience providing financial and accounting leadership to life sciences and technology companies, including more than 24 years serving as chief financial officer of public companies. Most recently, Mr. McDonnell served as Executive Vice President and Chief Financial Officer of Biogen Inc. from August 2020 through February 2025, where he oversaw investor relations, financial planning and analysis, treasury, accounting, tax, internal audit, procurement, information technology, and business unit finance. Since March 2025, he has served as an advisor to Goldman Sachs Asset Management. Prior to Biogen, Mr. McDonnell served as Executive Vice President and Chief Financial Officer of IQVIA Holdings Inc. following the merger of Quintiles and IMS Health. Earlier in his career, he served as Executive Vice President and Chief Financial Officer of Intelsat S.A., Executive Vice President and Chief Financial Officer of MCG Capital Corporation, and Chief Financial Officer of EchoStar Communications Corporation. He began his career at PricewaterhouseCoopers LLP, where he spent 14 years, including four years as a partner. Mr. McDonnell currently serves on the Board of Directors of Merit Medical Systems, Inc., where he chairs the Audit Committee, and on the Board of Directors of Baxter International Inc. He previously served on the Board of Directors of Catalyst Health Solutions until its acquisition.

Ms. Franklin oversees Moderna's talent, digital initiatives and organizational strategy. Ms. Franklin joined Moderna in October 2019 as our Chief Human Resources Officer, before becoming our Chief People and Digital Technology Officer in November 2024. Before joining Moderna, she was employed by Merck & Co. from 2004 to 2019 in positions of increasing responsibility, including most recently Vice President, HR Chief Talent and Strategy Officer. Ms. Franklin's previous leadership roles included responsibility for HR for all divisions in the European region, head of HR for the UK and Ireland subsidiaries of Merck, and HR Operations leader responsible for HR program implementation across Merck's global footprint. She was based in Switzerland, the UK and the U.S. Education: Pennsylvania State University, B.A. in Communication Arts and Sciences, Fairleigh Dickinson University, Masters in Industrial and Organizational Psychology.

Dr. Loughlin oversees Moderna's platform science and therapeutics research organization and is responsible for strengthening the Company's pipeline. Dr. Loughlin previously led our research and early development functions for several years, with responsibility for platform research, therapeutics discovery and non-clinical development. Before joining Moderna in 2016, Dr. Loughlin was employed by Biogen, Inc. from 2013 to 2015, in business development roles. Dr. Loughlin also previously worked at L.E.K. Consulting. Education: Harvard University, A.B. in Physics, University of California, Berkeley, Ph.D. in Biophysics.

Dr. David Berman, M.D., Before joining Moderna in March 2026, Dr. Berman was employed by Immunocore from 2018 to 2026, most recently as Executive Vice President and Head of Research and Development. He completed an anatomic pathology residency at the National Cancer Institute and a fellowship at the Johns Hopkins Hospital. Education: Massachusetts Institute of Technology, S.B. in Biology, University of Texas Southwestern Medical School, M.D., Ph.D.